Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 426-437

  Jézéquel, Pascal ^a   Campion, Loïc ^a   Spyratos, Frédérique ^b   Loussouarn, Delphine ^c   Campone, Mario ^a   Guérin Charbonnel, Catherine ^a   Joalland, Marie Pierre ^a   André, Jean ^d   Descotes, Françoise ^d   Grenot, Catherine ^d   Roy, Pascal ^e   Carlioz, Antoine ^f   Martin, Pierre Marie ^f   Chassevent, Agnès ^g   Jourdan, Marie Lise ^h   Ricolleau, Gabriel ^a  

^a Institut de cancerologie de l'Ouest Rene Gauducheau   (France)

^b INSTITUT CURIE   (France)

^c CHU de Nantes   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^g Institut de Cancérologie de l'Ouest Site Paul Papin   (France)

^h CHU BRETONNEAU   (France)

Author keywords

breast cancer; ferritin light chain; multicentric study; prognostic marker; tumor associated macrophage

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; CD86 ANTIGEN; FERRITIN; SYNDECAN 1; TUMOR MARKER; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN CONJUGATING ENZYME E2 C; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SCREENING; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IRON METABOLISM; LIGHT CHAIN; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL NOISE RATIO; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; VALIDATION PROCESS;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOFERRITINS; BREAST NEOPLASMS; CELL PROLIFERATION; COHORT STUDIES; CYTOSOL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MACROPHAGES; MIDDLE AGED; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84861598906     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26397     Document Type: Article

References (44)

1. Adjuvant therapy for breast cancer. NIH Consensus Statement 2000; 17: 1-35.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ,. Meetings highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 15: 3357-65.
3. van de Vijver MJ, He YD, van't Veer L, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
4. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-79.
5. Hutchens TW, Yip TT,. New desorption strategies for the mass spectrometric analysis of micromolecules. Rapid Commun Mass Spectrom 1993; 7: 576-80.
6. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW,. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-304.
7. Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004; 100: 1814-22.
8. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF, III,. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF; potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001; 17: 301-07.
9. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC,. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 2005; 114: 791-96.
10. Nakagawa T, Huang SK, Martinez SR, Tran AN, Elashoff D, Ye X, Turner RR, Giuliano AE, Hoon DSB,. Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Res 2006; 66: 11825-30.
11. Gonçalves A, Charafe-Jauffret E, Bertucci F, Audebert S, Toiron Y, Esterni B, Monville F, Tarpin C, Jacquemier J, Houvenaeghel G, Chabannon C, Extra JM, et al. Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 2008; 7.8: 20-1433.
12. Ricolleau G, Charbonnel C, Lodé L, Loussouarn D, Joalland MP, Bogumil R, Jourdain S, Minvielle S, Campone M, Déporte-Fety R, Campion L, Jézéquel P,. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node negative breast cancer tumors. Proteomics 2006; 6: 1963-75.
13. Brozkova K, Budinska E, Bouchal P, Hernychova L, Knoflikova D, Valik D, Vyzula R, Vojtesek B, Nenutil R,. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res 2008; 10: R48.
14. Klymkowsky MW, Savagner P,. Epithelial-mesenchymal transition. A cancer researcher's conceptual friend and foe. Am J Pathol 2009; 174: 1588-93.
15. Bradford MM,. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
16. Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G, Gouraud W, Bataille R, Jézéquel P,. Comparative prognostic value of UBE2C and Ki-67 immunohistochemistry staining in node-positive breast cancer. Br J Cancer 2009; 101: 166-73.
17. Rossiello R, Carriero MV, Giordano GG,. Distribution of ferritin, transferring and lactoferrin in breast carcinoma tissue. J Clin Pathol 1984; 37: 51-5.
18. Weinstein RE, Bond BH, Silberberg BK,. Tissue ferritin concentration in carcinoma of the breast. Cancer 1982; 50: 2406-9.
19. Weinstein RE, Bond BH, Silberberg BK, Vaughn CB, Subbaiah P, Pieper DR,. Tissue ferritin concentration and prognosis in carcinoma of the breast. Breast Cancer Res Treat 1989; 14: 349-353.
20. Torti FM, Torti SV,. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-16.
21. Sica A, Schioppa T, Mantovani A, Allavena P,. Tumor-associated macrophages are a distinct M2 polarised population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-27.
22. Corna G, Campana L, Pignatti E, Castiglioni A, Tagliafico E, Bosurgi L, Campanella A, Brunelli S, Manfredi AA, Apostoli P, Silvestri L, Camaschella C, et al. Polarization dictates iron handling by inflammatory and alternatively activated macropages. Haematologica 2010; 95: 1814-22.
23. Ignatiadis M, Sotiriou C,. Understanding the molecular basis of histologic grade. Pathobiology 2008; 75: 104-11.
24. Cozzi A, Corsi B, Levi S, Santambrogio P, Biasiotto G, Arosio P,. Analysis of the biologic functions of H- and L-ferritin in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin. Blood 2004; 103: 2377-83.
25. Nimeus E, Malmström J, Johnsson A, Marko-Varga G, Fernö M,. Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherpay. J Pharm Biomed Anal 2006; 43: 1086-93.
26. Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA, Pogribny IP,. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 2011; 126: 63-71.
27. Montovani A, Allavena P, Sica A, Blackwil F,. Cancer-related inflammation. Nature 2008; 454: 436-44.
28. Bolat F, Kayaselcuk F, Nursal TZ, Yagmudur MC, Bal N, Demirhan B,. Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res 2006; 25: 365-72.
29. Pollard JW,. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008; 84: 623-30.
30. Qian BZ, Pollard JW,. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
31. Volodko N, Reiner A, Rudas M, Jakesz R,. Tumour-associated macrophages in breast cancer and their prognostic correlations. Breast 1998; 7: 99-105.
32. Bingle L, Brown NJ, Lewis CE,. The role of tumor-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-65.
33. Lin CY, Lin CJ, Chen KH, Wu JC, Huang SH, Wang SM,. Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett 2006; 580: 3042-50.
34. Recalcati S, Locati M, Marini A, Santambrogio P, Zaninotto F, De Pizzol M, Zammataro L, Girelli D, Cairo G,. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol 2010; 40: 824-35.
35. Güner G, Kirkali G, Yenisey C, Töre IR,. Cytosol and serum ferritin in breast carcinoma. Cancer Lett 1992; 67: 103-12.
36. Lieghr JG, Jones JS,. Role of iron in estrogen-induced cancer. Curr Med Chem 2001; 8: 839-49.
37. Kabat GC, Rohan TE,. Does excess iron play a role in breast carcinogenesis? An unresolved hypohesis. Cancer Causes Control 2007; 18: 1047-1053.
38. Huang X,. Does iron have a role in breast cancer? Lancet Oncol 2008; 9: 803-07.
39. Pinnix Z, Miller LD, Wang W, D'Agostino R, Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM,. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Trans Med 2010; 2: 43ra56.
40. Fargion S, Valenti L, Fracanzani AL,. Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overload. Hepatology 2010; 51: 1119-21.
41. Coffman LG, Parsonage D, D'Agostino R, Torti FM, Torti SV,. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci USA 2009; 106: 570-5.
42. Le NT, Richardson DR,. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004; 104: 2967-75.
43. Nurtjahja-Tjenddraputra E, Fu D, Phang JM, Richardson DR,. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood 2007; 109: 4045-54.
44. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB,. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 2009; 1790: 702-17.